What is the share price of Rossari Biotech Ltd (ROSSARI) today?
The share price of ROSSARI as on 10th July 2025 is ₹700.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Rossari Biotech Ltd (ROSSARI) share?
The past returns of Rossari Biotech Ltd (ROSSARI) share are- Past 1 week: 5.07%
- Past 1 month: 2.15%
- Past 3 months: 2.03%
- Past 6 months: -14.52%
- Past 1 year: -14.11%
- Past 3 years: -18.23%
- Past 5 years: -5.53%
What are the peers or stocks similar to Rossari Biotech Ltd (ROSSARI)?
The peers or stocks similar to Rossari Biotech Ltd (ROSSARI) include:What is the dividend yield % of Rossari Biotech Ltd (ROSSARI) share?
The current dividend yield of Rossari Biotech Ltd (ROSSARI) is 0.07.What is the market cap of Rossari Biotech Ltd (ROSSARI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Rossari Biotech Ltd (ROSSARI) is ₹3878.98 Cr as of 10th July 2025.What is the 52 week high and low of Rossari Biotech Ltd (ROSSARI) share?
The 52-week high of Rossari Biotech Ltd (ROSSARI) is ₹972.70 and the 52-week low is ₹569.What is the PE and PB ratio of Rossari Biotech Ltd (ROSSARI) stock?
The P/E (price-to-earnings) ratio of Rossari Biotech Ltd (ROSSARI) is 28.44. The P/B (price-to-book) ratio is 3.27.Which sector does Rossari Biotech Ltd (ROSSARI) belong to?
Rossari Biotech Ltd (ROSSARI) belongs to the Materials sector & Specialty Chemicals sub-sector.How to buy Rossari Biotech Ltd (ROSSARI) shares?
You can directly buy Rossari Biotech Ltd (ROSSARI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Rossari Biotech Ltd
ROSSARI Share Price
700.600.60% (-4.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ROSSARI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ROSSARI Performance & Key Metrics
ROSSARI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 28.44 | 3.27 | 0.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 27.93 | 3.47 | 1.60% |
100%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
ROSSARI Company Profile
Rossari Biotech is engaged in business of textile and specialty chemical manufacturing.
FLUOROCHEM
PE Ratio
68.70
68.70
1Y Return
6.04%
6.04%
Buy Reco %
55.56
55.56
NAVINFLUOR
PE Ratio
86.00
86.00
1Y Return
36.19%
36.19%
Buy Reco %
62.96
62.96
VINATIORGA
PE Ratio
50.31
50.31
1Y Return
2.82%
2.82%
Buy Reco %
83.33
83.33
AKZOINDIA
PE Ratio
38.18
38.18
1Y Return
23.29%
23.29%
Buy Reco %
50.00
50.00
AARTIIND
PE Ratio
49.07
49.07
1Y Return
36.05%
36.05%
Buy Reco %
70.59
70.59
ROSSARI Sentiment Analysis
ROSSARI Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ROSSARI Stock Summary · May 2025
The company has achieved a remarkable 13.6% year-over-year revenue growth, bolstered by a diversified portfolio and strategic investments in emerging verticals, despite facing rising operational costs and margin pressures. With a focus on sustainable solutions and innovation, it is enhancing its market position as a one-stop shop for major clients, while navigating challenges in raw material pricing and geopolitical uncertainties. The successful commercialization of new product platforms, particularly in the HPPC and Buzil segments, is expected to drive future profitability, although negative EBITDA remains a concern in the short term. As the company expands its production capabilities and integrates backward, it aims to stabilize costs and achieve targeted EBITDA margins, positioning itself for long-term growth amidst a dynamic market landscape.
ROSSARI Stock Growth Drivers
ROSSARI Stock Growth Drivers
6Strong Financial Performance
In FY25, the company reported a revenue from operations of Rs. 2,080 crore, marking a
Expansion and Investment Initiatives
The company is advancing multiple expansion projects, with ongoing expansions at Dahej and Unitop on
ROSSARI Stock Challenges
ROSSARI Stock Challenges
6Declining EBITDA Margins
The company has reported a decline in EBITDA margins, with the margin for Q4 FY25
Negative Performance in Buzil Segment
The Buzil segment is experiencing negative EBITDA despite an increase in revenue, indicating that the
ROSSARI Forecast
ROSSARI Forecasts
Price
Revenue
Earnings
ROSSARI Share Price Forecast
ROSSARI Share Price Forecast
2025
Current
₹700.60
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹700.60
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ROSSARI Company Revenue Forecast
ROSSARI Company Revenue Forecast
2025
Current
₹2.09
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹2.09
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ROSSARI Stock EPS (Earnings Per Share) Forecast
ROSSARI Stock EPS (Earnings Per Share) Forecast
2025
Current
₹24.66
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹24.66
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ROSSARI
ROSSARI
Income
Balance Sheet
Cash Flow
Annual Normal View
ROSSARI Income Statement
ROSSARI Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 517.13 | 603.81 | 718.47 | 1,496.51 | 1,662.32 | 1,838.18 | 2,085.28 | 2,085.28 | ||||||||
Raw Materials | 355.23 | 369.26 | 470.62 | 1,128.08 | 1,183.96 | 1,357.04 | 1,464.41 | 1,815.21 | ||||||||
| Power & Fuel Cost | 1.26 | 1.74 | 2.40 | 11.92 | 20.40 | 23.30 | 25.91 | |||||||||
| Employee Cost | 27.52 | 37.21 | 41.98 | 67.93 | 98.62 | 103.13 | 132.33 | |||||||||
| Selling & Administrative Expenses | 38.07 | 50.79 | 36.70 | 37.93 | 58.89 | 61.54 | 97.60 | |||||||||
| Operating & Other expenses | 16.59 | 36.57 | 34.11 | 53.67 | 71.00 | 35.79 | 94.96 | |||||||||
EBITDA | 78.46 | 108.24 | 132.66 | 196.98 | 229.45 | 257.38 | 270.07 | 270.07 | ||||||||
| Depreciation/Amortization | 12.19 | 16.85 | 22.83 | 48.06 | 62.93 | 60.39 | 67.07 | 67.07 | ||||||||
| PBIT | 66.27 | 91.39 | 109.83 | 148.92 | 166.52 | 196.99 | 203.00 | 203.00 | ||||||||
| Interest & Other Items | 2.88 | 3.56 | 2.99 | 12.66 | 22.32 | 19.37 | 17.81 | 17.81 | ||||||||
| PBT | 63.39 | 87.83 | 106.84 | 136.26 | 144.20 | 177.62 | 185.19 | 185.19 | ||||||||
| Taxes & Other Items | 17.71 | 22.58 | 26.62 | 38.60 | 36.96 | 46.93 | 48.81 | 48.80 | ||||||||
| Net Income | 45.68 | 65.25 | 80.22 | 97.66 | 107.24 | 130.69 | 136.38 | 136.39 | ||||||||
| EPS | 9.44 | 13.16 | 15.62 | 18.26 | 19.46 | 23.68 | 24.66 | 24.64 | ||||||||
| DPS | 0.00 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | ||||||||
| Payout ratio | 0.00 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
ROSSARI Company Updates
ROSSARI Stock Peers
ROSSARI Past Performance & Peer Comparison
ROSSARI Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsSpecialty Chemicals
Compare valuation-basic on Screener
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Rossari Biotech Ltd | 28.44 | 3.27 | 0.07% |
| Gujarat Fluorochemicals Ltd | 68.70 | 6.32 | 0.09% |
| Navin Fluorine International Ltd | 86.00 | 9.45 | 0.14% |
| Vinati Organics Ltd | 50.31 | 8.28 | 0.38% |
ROSSARI Stock Price Comparison
Compare ROSSARI with any stock or ETFCompare ROSSARI with any stock or ETF
ROSSARI
ROSSARI Holdings
ROSSARI Shareholdings
ROSSARI Promoter Holdings Trend
ROSSARI Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ROSSARI Institutional Holdings Trend
ROSSARI Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ROSSARI Shareholding Pattern
ROSSARI Shareholding Pattern
ROSSARI Shareholding History
ROSSARI Shareholding History
Foreign Institutions
Mutual Funds Invested in ROSSARI
Mutual Funds Invested in ROSSARI
No mutual funds holding trends are available
Top 5 Mutual Funds holding Rossari Biotech Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.5682% | Percentage of the fund’s portfolio invested in the stock 0.39% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 59/71 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 3.0915% | Percentage of the fund’s portfolio invested in the stock 0.46% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/64 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.9234% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 91/106 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ROSSARI stock
smallcases containing ROSSARI stock
Looks like this stock is not in any smallcase yet.
ROSSARI Events
ROSSARI Events
ROSSARI Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ROSSARI has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.71 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ROSSARI Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ROSSARI has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.71 every year
ROSSARI Upcoming Dividends
ROSSARI Upcoming Dividends
No upcoming dividends are available
ROSSARI Past Dividends
ROSSARI Past Dividends
Cash Dividend
Ex DateEx DateJun 20, 2025
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 20, 2025
Cash Dividend
Ex DateEx DateAug 16, 2024
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Aug 16, 2024
Cash Dividend
Ex DateEx DateMay 24, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
May 24, 2023
Cash Dividend
Ex DateEx DateJul 7, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
ROSSARI Stock News & Opinions
ROSSARI Stock News & Opinions
Articles & Videos
Corporate
Rossari Biotech schedules AGM
Rossari Biotech announced that the 16th Annual General Meeting(AGM) of the company will be held on 30 June 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Rossari Biotech Q4 PAT rises to Rs 34 crore in FY25
However, revenue from operations jumped 22.60% to Rs 579.56 crore in the fourth quarter of FY25 as against Rs 472.72 crore posted in the corresponding quarter last year. Profit before tax stood at Rs 47.71 crore in the quarter ended 31 March 2025, up 4.69% as against Rs 45.57 crore recorded in Q4 FY24. Total expenses rose 24.79% to Rs 533.79 crore during the quarter. Cost of material consumed stood at Rs 369.77 crore (up 21.65% YoY), employee benefit expenses stood at Rs 35.48 crore (up 41.69%), and finance costs were at Rs 5.50 crore (up 118.25% YoY) during the period under review. EBITDA dropped 9.27% to Rs 69.5 crore in the quarter ended 31 March 2025 as compared to Rs 63.6 crore posted in the same quarter the previous year. EBITDA margin reduced to 12% in Q4 FY25 as against 13.5% recorded in Q4 FY24. On a full-year basis, the company's consolidated net profit rose 4.35% to Rs 136.38 crore on 13.64% rise in revenue to Rs 2,080.29 crore in FY25 over FY24. Commenting on the performance, in a joint statement, Edward Menezes, promoter & executive chairman, and Sunil Chari, promoter & managing director, said, 'We concluded the year with a steady performance, navigating a soft and evolving operating environment. Revenues grew by 14% driven by healthy export momentum and resilient volumes across key categories. The HPPC segment remained the primary growth driver, supported by deeper market penetration and strong traction across agrochemicals, personal care, institutional and consumer business. The TSC and AHN segments recorded modest revenue growth, contributing positively to the overall performance. We remain optimistic about their medium-to-long-term potential, supported by ongoing portfolio optimization efforts Export markets continued to perform well during the year, validating our strategic investments in global partnerships and differentiated solutions. We are also encouraged by the growing momentum in emerging verticals such as institutional cleaning and B2C businesses, which reflect our ability to build scalable, value-added platforms aligned with evolving customer needs. We continue to invest in capacity enhancement to strengthen our growth foundation and are pleased to announce an additional capex of Rs 97 crore for expansions at our subsidiaries, Unitop Chemicals and Tristar Intermediates, along with Rs 95 crore at Rossari Biotech. These projects, expected to be commissioned in a phased manner by Q4 FY26, are aimed at supporting growth across our key chemistries, improving operational efficiency, and enhancing supply reliability. Our previously announced expansion projects are progressing well, with commissioning expected by Q2 FY26. With these capacity additions, we are well-positioned to meet growing demand across end-user industries. Looking ahead, we remain focused on delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, we are confident in our ability to maintain healthy growth momentum in the coming years.' Meanwhile, the company's board has declared a final dividend of Rs 0.50 per share each for the financial year ended 31 March 2025, which shall be paid/dispatched within 10 working days from the conclusion of the 16th Annual General Meeting, subject to approval of the members of the company. Rossari Biotech is a specialty chemical manufacturer and offers tailor-made solutions for home, personal care and performance chemicals (HPPC), textile speciality chemicals and animal health and nutrition (AHN). The counter shed 0.79% to Rs 693.25 on the BSE. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Board of Rossari Biotech recommends final dividend
Rossari Biotech announced that the Board of Directors of the Company at its meeting held on 25 April 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Rossari Biotech consolidated net profit rises 0.91% in the March 2025 quarter
Net profit of Rossari Biotech rose 0.91% to Rs 34.44 crore in the quarter ended March 2025 as against Rs 34.13 crore during the previous quarter ended March 2024. Sales rose 22.60% to Rs 579.56 crore in the quarter ended March 2025 as against Rs 472.72 crore during the previous quarter ended March 2024. For the full year,net profit rose 4.35% to Rs 136.38 crore in the year ended March 2025 as against Rs 130.69 crore during the previous year ended March 2024. Sales rose 13.64% to Rs 2080.29 crore in the year ended March 2025 as against Rs 1830.56 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales579.56472.72 23 2080.291830.56 14 OPM %11.9913.45 -12.7413.64 - PBDT65.9361.64 7 252.26238.01 6 PBT47.7145.57 5 185.19177.62 4 NP34.4434.13 1 136.38130.69 4 Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Rossari Biotech standalone net profit rises 23.65% in the March 2025 quarter
Net profit of Rossari Biotech rose 23.65% to Rs 32.36 crore in the quarter ended March 2025 as against Rs 26.17 crore during the previous quarter ended March 2024. Sales rose 35.96% to Rs 426.65 crore in the quarter ended March 2025 as against Rs 313.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 15.14% to Rs 114.74 crore in the year ended March 2025 as against Rs 99.65 crore during the previous year ended March 2024. Sales rose 19.01% to Rs 1431.63 crore in the year ended March 2025 as against Rs 1202.91 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales426.65313.80 36 1431.631202.91 19 OPM %12.2313.30 -13.0113.41 - PBDT51.5141.33 25 182.39158.33 15 PBT43.8534.75 26 154.70134.14 15 NP32.3626.17 24 114.7499.65 15 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Rossari Biotech to announce Quarterly Result
Rossari Biotech will hold a meeting of the Board of Directors of the Company on 25 April 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Rossari Biotech slides after PAT tumble 8% YoY to Rs 32 cr in Q3 FY25
However, revenue from operations jumped 10.55% to Rs 512.73 crore in the third quarter of FY25 as against Rs 463.77 crore posted in the corresponding quarter last year. Profit before tax stood at Rs 42.38 crore in the quarter ended 31 December 2024, down 11.30% as against Rs 47.78 crore recorded in Q3 FY24. Total expenses advanced 12.32% to Rs 471.23 crore during the quarter. Cost of material consumed stood at Rs 321.48 crore (down 17.78% YoY), employee benefit expenses stood at Rs 35.69 crore (up 37.07%) while finance cost was at Rs 4.94 crore (up 14.35% YoY), during the period under review. On nine-month basis, the company's standalone net profit rose 5.56% to Rs 101.93 crore on 10.52% increase in revenue to Rs 1,500.7 crore in 9M FY25 over 9M FY24. Rossari Biotech is a specialty chemical manufacturer and offers tailor-made solutions for home, personal care and performance chemicals (HPPC), textile speciality chemicals and animal health and nutrition (AHN). Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Rossari Biotech consolidated net profit declines 7.82% in the December 2024 quarter
Net profit of Rossari Biotech declined 7.82% to Rs 31.70 crore in the quarter ended December 2024 as against Rs 34.39 crore during the previous quarter ended December 2023. Sales rose 10.56% to Rs 512.73 crore in the quarter ended December 2024 as against Rs 463.77 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales512.73463.77 11 OPM %12.6313.73 - PBDT60.7062.87 -3 PBT42.3847.78 -11 NP31.7034.39 -8 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Rossari Biotech shifts registered office
The board of Rossari Biotech at its meeting held on 21 January 2025 has approved change in registered office from 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078 to Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai Maharashtra, India, 400079 effective from 01 February 2025. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Rossari Biotech allots 7,5000 equity shares under ESOP
Rossari Biotech has allotted 7,500 equity shares under ESOP on 21 January 2025. Consequently, the paid up equity share capital has increased to Rs. 11,07,27,532 consisting of 55363766 equity shares of Rs. 2/- each.Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 28.13%, vs industry avg of 11.02%
Over the last 5 years, market share increased from 1.13% to 2.21%
Over the last 5 years, net income has grown at a yearly rate of 15.89%, vs industry avg of 7.7%